SCHEMBL6109342

SCHEMBL6109342

CC(C)(O)Cc1ccc(C(=O)C2CC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ MEN1 O00255 3/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ HTR2A P28223 3/20 0.42
▸ HTR2C P28335 2/20 0.42
▸ HTR7 P34969 1/20 0.42
▸ HTR6 P50406 1/20 0.42
▸ HRH3 Q9Y5N1 1/20 0.41
▸ HTR2B P41595 1/20 0.40
▸ THRA P10827 1/20 0.40
▸ THRB P10828 1/20 0.40
▸ KDM1A O60341 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ SRD5A2 P31213 1/20 0.40
▸ MGLL Q99685 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18290660 0.81 HTR2A (0.47) NPC1RAB9AHTR2AHTR2CHTR7
SCHEMBL3678830 0.78 MGLL (0.56) NPC1RAB9AMEN1KMT2ACYP2D6
SCHEMBL19754954 0.77 KMT2A (0.53) NPC1RAB9AMEN1KMT2ACYP2D6
SCHEMBL12491968 0.76 ALDH1A1 (0.57) MEN1KMT2ATHRATHRBTP53
SCHEMBL2925097 0.75 MEN1 (0.49) NPC1RAB9AMEN1KMT2ACYP2D6
SCHEMBL11010359 0.75 MGLL (0.58) NPC1RAB9AKMT2AHTR2AHTR2C
SCHEMBL13084751 0.75 NPC1 (0.49) NPC1RAB9AMEN1KMT2ACYP2D6
SCHEMBL11010367 0.75 MGLL (0.58) NPC1RAB9AKMT2AHTR2AHTR2C
SCHEMBL28975172 0.74 HTR2A (0.45) NPC1RAB9AMEN1KMT2ACYP2D6
SCHEMBL3674393 0.74 RAB9A (0.51) NPC1RAB9AMEN1KMT2ACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060173042-A1 Process for the preparation of fexofenadine RANBAXY LABORATORIES LIMITED (IN) 2006-08-03 — — US claimed
EP-1575893-A1 PROCESS FOR THE PREPARATION OF FEXOFENADINE Ranbaxy Laboratories Limited (IN) 2005-09-21 — — EP claimed
WO-2004054955-A1 PROCESS FOR THE PREPARATION OF FEXOFENADINE RANBAXY LABORATORIES LIMITED (US) 2004-07-01 — — WO claimed
US-20060173042-A1 Process for the preparation of fexofenadine RANBAXY LABORATORIES LIMITED (IN) 2006-08-03 — — US disclosed
EP-1575893-A1 PROCESS FOR THE PREPARATION OF FEXOFENADINE Ranbaxy Laboratories Limited (IN) 2005-09-21 — — EP disclosed
WO-2004054955-A1 PROCESS FOR THE PREPARATION OF FEXOFENADINE RANBAXY LABORATORIES LIMITED (US) 2004-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060173042-A1 Process for the preparation of fexofenadine CMA1, HRH2, MAOA NPC1 3232/4885RAB9A 2049/4885MEN1 1953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback